These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30055090)

  • 1. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment pathways in an inception lupus cohort over the first three years.
    Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
    Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining Low Disease Activity in Systemic Lupus Erythematosus.
    Polachek A; Gladman DD; Su J; Urowitz MB
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):997-1003. PubMed ID: 27696791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged clinical remission in patients with systemic lupus erythematosus.
    Steiman AJ; Urowitz MB; Ibañez D; Papneja A; Gladman DD
    J Rheumatol; 2014 Sep; 41(9):1808-16. PubMed ID: 25086082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2019 Jun; 48(6):1035-1040. PubMed ID: 30415943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged remission in systemic lupus erythematosus.
    Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
    J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.
    Ugarte-Gil MF; Wojdyla D; Pastor-Asurza CA; Gamboa-Cárdenas RV; Acevedo-Vásquez EM; Catoggio LJ; García MA; Bonfá E; Sato EI; Massardo L; Pascual-Ramos V; Barile LA; Reyes-Llerena G; Iglesias-Gamarra A; Molina-Restrepo JF; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
    Lupus; 2018 Apr; 27(4):536-544. PubMed ID: 28857715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index.
    Touma Z; Gladman DD; Zandy M; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1243-1249. PubMed ID: 32433815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
    Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
    Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monophasic Disease Course in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    J Rheumatol; 2018 Aug; 45(8):1131-1135. PubMed ID: 29858240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Barber MRW; Ugarte-Gil MF; Hanly JG; Urowitz MB; St-Pierre Y; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Pons-Estel BA; Cardwell FS; Alarcón GS; Clarke AE
    Ann Rheum Dis; 2024 Sep; 83(10):1295-1303. PubMed ID: 38754981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
    J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.
    Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Mitjavila F; Castro Salomó A; Cuquet Pedragosa J; Ortiz-Santamaria V; Mauri Plana M; Cortés-Hernández J
    Ann Rheum Dis; 2017 Sep; 76(9):1575-1582. PubMed ID: 28450313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
    Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.